Mesothelioma Articles

Phase I Study of Intrapleural BG00001 in Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Date First Published: 2003-07-26

BASIC STUDY INFORMATION

PATIENT ABSTRACT:

Rationale:
Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.

Purpose:
Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural effusions.

Eligibility:
 •At least 18 years old
 •Measurable or evaluable disease
 •More than 4 weeks since biological therapy or radiation therapy
 •No previous bone marrow transplantation or stem cell transplantation
 •At least 2 weeks since surgery

Treatment Intervention:
A catheter will be placed between the lung and chest wall through which BG00001 will be infused. Patients will be evaluated once a week for 1 month, twice a month for 1 month, once a month for 4 months, and every 6 months for 15 years.

Disclaimer:
This abstract is intended to give a brief overview of this clinical trial. To help determine whether the trial is appropriate for an individual, selected major eligibility criteria are listed above. To obtain more details related to trial eligibility and the treatment plan, please see the Health Professional abstract of this clinical trial. Information about ongoing clinical trials is available from the NCI Cancer.gov Web site.

STUDY LEAD ORGANIZATIONS:
 Abramson Cancer Center of the University of Pennsylvania
 Daniel Sterman, MD, Protocol chair
 Ph: 215-614-0984

STUDY SITES AND CONTACTS

U.S.A.

Pennsylvania

 Abramson Cancer Center of the University of Pennsylvania
 Adri Recio, RN
 Ph: 215-573-6760

 Daniel Sterman, MD
 Ph: 215-614-0984

 Larry Kaiser, MD
 Ph: 215-662-7538
 kaiser@uphs.upenn.edu

 Steven Albelda, MD
 Ph: 215-349-8382

Source: Cancer.gov

MIRG.org 1-888-802-6376 e-mail

www.MIRG.org • Site Map • About Us • Contact Us • Links • Disclaimer